Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: Ophthalmology. 2016 Jul 15;123(9):1912–1918. doi: 10.1016/j.ophtha.2016.05.037

Figure 2.

Figure 2

Estimated cost utility of additional therapy beyond 2 years (panretinal photocoagulation [PRP] and intravitreal injection ranibizumab [IVR]). QALY = quality-adjusted life year.